AlphaMet

Company Overview

Snapshot

Founded in May 2012 by Rafi Herzog, AlphaMet operates with 1–10 employees. The company has raised $820,000 across three funding rounds from one investor. AlphaMet's CyclaPlex Correction System, an implant device for bunion surgery, received FDA clearance for use by surgeons.

Business overview

AlphaMet, formerly known as CyclaPlex, develops, manufactures, and markets the CyclaPlex Correction System. This implant device is designed to prevent bone osteotomy, shorten recovery time, reduce pain, and facilitate patient recovery within days of bunion surgery. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers.

Company Intelligence Q&A

What is AlphaMet's primary product?

AlphaMet's primary product is the CyclaPlex Correction System, an implant device designed for bunion surgery to prevent bone osteotomy, shorten recovery time, and reduce pain.

When was AlphaMet founded and by whom?

AlphaMet was founded in May 2012 by Rafi Herzog.

Has AlphaMet's product received regulatory clearance?

Yes, the CyclaPlex Correction System received FDA clearance for use by surgeons. This clearance allows the device to be marketed and used in medical procedures within the United States.

What is the distribution strategy for CyclaPlex in the U.S.?

The CyclaPlex Correction System is distributed in the U.S. by Genesis Ortho Partners.

What was a key milestone for AlphaMet in February 2017?

In February 2017, news reported that the Israeli company AlphaMet would treat bunions worldwide, indicating an expansion of its market reach.